

Data Sharing Statement

Motzer. Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. *JAMA Oncol*. Published December 23, 2021. doi:10.1001/jamaoncol.2021.5981

Data

Data available: Yes

Data types: Other (please specify)

Additional Information: Qualified researchers may request access to individual patient level data through the clinical study data request platform (<https://vivli.org/>). Further details on Roche's criteria for eligible studies are available here (<https://vivli.org/members/ourmembers/>). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

How to access data: <https://vivli.org>

When available: With publication

Supporting Documents

Document types: None

Additional Information

Who can access the data: Qualified researchers

Types of analyses: Individual patient level data

Mechanisms of data availability: Clinical study data request platform: <https://vivli.org>. Further details on Roche's criteria for eligible studies are available here (<https://vivli.org/members/ourmembers/>).